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Objective:  Lymphoid enhancing factor-
1 (Lef-1) is a transcription factor and 
downstream target of Wnt\β-catenin 
signaling.  Dysregulation of the Wnt\β-
catenin\Lef-1 signaling pathway has 
been implicated in cancer formation.  
We hypothesize that Lef-1 is 
overexpressed in ovarian, fallopian tube 
and peritoneal cancers, and is 
associated with adverse clinical and 
pathologic factors. 
Methods: Using our divisional database 
we identified patients diagnosed with 
epithelial ovarian, fallopian tube and/or 
primary peritoneal cancer.  Lef-1 mRNA 
levels were determined in tumor tissue 
using Real Time (RT) PCR, and p53 
mutations were determined by direct 
sequencing. Clinical data included age 
at diagnosis, recurrence history, 
platinum sensitivity, stage, grade, 
histology, degree of cytoreduction, 
additional p53 mutational status, and 
follow up that were collected from a 
retrospective chart review.  Lef-1 mRNA 
levels were compared to clinical and 
pathological data using ANOVA, chi 
square analysis and survival was 
analyzed using the log rank test.  
Results:  We identified 51 patients with 
ovarian, fallopian tube or peritoneal 
carcinoma.  Lef-1 mRNA levels were 
significantly elevated in tumor samples 
when compared to non-cancerous 
controls (p=0.0001). Elevated Lef-1 
mRNA levels were significantly 
associated with advanced stage 
(p=0.04), and serous histology (p=0.01).  
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Patients with a greater than or equal to 
2.5 fold increase in Lef-1 mRNA 
expression had an overall survival of 
28% compared to a 57% five year 
overall survival for patients with less 
than a 2.5 fold increase (p=0.08).  
Conclusions: Lef-1 mRNA levels were 
statistically elevated in cases of ovarian, 
fallopian tube or peritoneal cancer when 
compared to non-cancerous controls.  
Among cancer cases, levels of Lef-1 
were statistically different between stage 
and histology.  Lef-1 overexpression 
may be predictive of poor overall 
survival. These findings suggest that 
Lef-1 overexpression may contribute to 
ovarian, fallopian tube and peritoneal 
carcinogenesis, and that further 
investigation is warranted.  
 
